|
1
|
Nelson NJ: Pancreatic cancer research
matures. J Natl Cancer Inst. 99:1432–1434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neoptolemos JP, Stocken DD, Bassi C,
Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger
S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus
folinic acid vs gemcitabine following pancreatic cancer resection:
A randomized controlled trial. JAMA. 304:1073–1081. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Cutsem E, Vervenne WL, Bennouna J,
Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang
A, Cosaert J and Moore MJ: Phase III trial of bevacizumab in
combination with gemcitabine and erlotinib in patients with
metastatic pancreatic cancer. J Clin Oncol. 27:2231–2237. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riley T, Sontag E, Chen P and Levine A:
Transcriptional control of human p53-regulated genes. Nat Rev Mol
Cell Biol. 9:402–412. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirao A, Kong YY, Matsuoka S, Wakeham A,
Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW: DNA
damage-induced activation of p53 by the checkpoint kinase Chk2.
Science. 287:1824–1827. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sakaguchi K, Herrera JE, Saito S, Miki T,
Bustin M, Vassilev A, Anderson CW and Appella E: DNA damage
activates p53 through a phosphorylation-acetylation cascade. Genes
Dev. 12:2831–2841. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Collado M and Serrano M: Senescence in
tumours: Evidence from mice and humans. Nat Rev Cancer. 10:51–57.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kastan MB, Canman CE and Leonard CJ: P53,
cell cycle control and apoptosis: Implications for cancer. Cancer
Metastasis Rev. 14:3–15. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghaneh P, Greenhalf W, Humphreys M, Wilson
D, Zumstein L, Lemoine NR and Neoptolemos JP: Adenovirus-mediated
transfer of p53 and p16(INK4a) results in pancreatic cancer
regression in vitro and in vivo. Gene Ther. 8:199–208. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu J, Zhu Y, Xu C, Xu H, Zhou X, Yang J,
Xie Y and Tao M: Adenovirus-mediated p53 and ING4 gene co-transfer
elicits synergistic antitumor effects through enhancement of p53
acetylation in breast cancer. Oncol Rep. 35:243–252. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rosenfeldt MT, O'Prey J, Morton JP, Nixon
C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, et al:
p53 status determines the role of autophagy in pancreatic tumour
development. Nature. 504:296–300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weill D, Mack M, Roth J, Swisher S,
Proksch S, Merritt J and Nemunaitis J: Adenoviral-mediated p53 gene
transfer to non-small cell lung cancer through endobronchial
injection. Chest. 118:966–970. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ginn SL, Alexander IE, Edelstein ML, Abedi
MR and Wixon J: Gene therapy clinical trials worldwide to 2012 - an
update. J Gene Med. 15:65–77. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Merritt JA, Roth JA and Logothetis CJ:
Clinical evaluation of adenoviral-mediated p53 gene transfer:
Review of INGN 201 studies. Semin Oncol. 28 5 Suppl 16:S105–S114.
2001. View Article : Google Scholar
|
|
16
|
Vousden KH and Prives C: Blinded by the
light: The growing complexity of p53. Cell. 137:413–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolchok JD, Hoos A, O'Day S, Weber JS,
Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al:
Guidelines for the evaluation of immune therapy activity in solid
tumors: Immune-related response criteria. Clin Cancer Res.
15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu TJ, Zhang WW, Taylor DL, Roth JA,
Goepfert H and Clayman GL: Growth suppression of human head and
neck cancer cells by the introduction of a wild-type p53 gene via a
recombinant adenovirus. Cancer Res. 54:3662–3667. 1994.PubMed/NCBI
|
|
21
|
Shimada H, Shimizu T, Ochiai T, Liu TL,
Sashiyama H, Nakamura A, Matsubara H, Gunji Y, Kobayashi S, Tagawa
M, et al: Preclinical study of adenoviral p53 gene therapy for
esophageal cancer. Surg Today. 31:597–604. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lang FF, Bruner JM, Fuller GN, Aldape K,
Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR,
et al: Phase I trial of adenovirus-mediated p53 gene therapy for
recurrent glioma: Biological and clinical results. J Clin Oncol.
21:2508–2518. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ternovoi VV, Curiel DT, Smith BF and
Siegal GP: Adenovirus-mediated p53 tumor suppressor gene therapy of
osteosarcoma. Lab Invest. 86:748–766. 2006.PubMed/NCBI
|
|
24
|
Scarpa A, Capelli P, Mukai K, Zamboni G,
Oda T, Iacono C and Hirohashi S: Pancreatic adenocarcinomas
frequently show p53 gene mutations. Am J Pathol. 142:1534–1543.
1993.PubMed/NCBI
|
|
25
|
Tomaszewska R, Karcz D and Stachura J: An
immunohistochemical study of the expression of bcl-2 and p53
oncoproteins in pancreatic intraepithelial neoplasia and pancreatic
cancer. Int J Pancreatol. 26:163–171. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weissmueller S, Manchado E, Saborowski M,
JP IV Morris, Wagenblast E, Davis CA, Moon SH, Pfister NT,
Tschaharganeh DF, Kitzing T, et al: Mutant p53 drives pancreatic
cancer metastasis through cell-autonomous PDGF receptor β
signaling. Cell. 157:382–394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang SW, Xiao SW, Liu CQ, Sun Y, Su X, Li
DM, Xu G, Cai Y, Zhu GY, Xu B and Lü YY: Treatment of head and neck
squamous cell carcinoma by recombinant adenovirus-p53 combined with
radiotherapy: A phase II clinical trial of 42 cases. Zhonghua Yi
Xue Za Zhi. 83:2023–2083. 2003.(In Chinese). PubMed/NCBI
|
|
28
|
Nemunaitis J, Swisher SG, Timmons T,
Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp
BL, et al: Adenovirus-mediated p53 gene transfer in sequence with
cisplatin to tumors of patients with non-small-cell lung cancer. J
Clin Oncol. 18:609–622. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li N, Zhou J, Weng D, Zhang C, Li L, Wang
B, Song Y, He Q, Lin D, Chen D, et al: Adjuvant adenovirus-mediated
delivery of herpes simplex virus thymidine kinase administration
improves outcome of liver transplantation in patients with advanced
hepatocellular carcinoma. Clin Cancer Res. 13:5847–5854. 2007.
View Article : Google Scholar : PubMed/NCBI
|
